KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory…

Overview of attention for article published in Blood, November 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

patent: 2 patents

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 2 patents that reference this research output.

Methods and combinations for treatment and T cell modulation

Grant US-12263190-B2

United States of America

COMBINATION THERAPIES WITH BCMA-DIRECTED T CELL THERAPY

Application WO-2022221726-A3

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity.